Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 830 results for "nexium"

Ranbaxy files lawsuit against US FDA's Valcyte and Nexium rulings
Business Standard India

Us overturns ranbaxy bid to block launch of nexium, valcyte ge...

The U.S. District Court of Minneapolis has denied a request by Indian drug maker Ranbaxy Laboratories to stop competitors from launching copies of Nexium and Valcyte. Nexium is a proprietary heartburn drug from AstraZeneca Plc , while ... 4 Traders, 12 hours ago

35 images for nexium

NDTV Profit, 1 week ago
Money Today, 1 week ago
Jagran Post, 1 week ago
Yahoo! News Australia, 1 week ago, 1 week ago
Money Control, 1 week ago, 4 hours ago
US News & World Report, 5 hours ago
Healthcare Global, 1 week ago
Business Standard India, 4 days ago
Irish Examiner

AstraZeneca Loses Bid to End Pay-For-Delay Nexium Trial

AstraZeneca Plc (AZN) and Ranbaxy Laboratories Ltd. (RBXY) failed to derail a landmark trial in the U.S. accusing the companies of colluding to delay the release of a cheaper version of the top-selling heartburn pill Nexium. U.S. District Judge ...
 BusinessWeek1 day ago AstraZeneca, Ranbaxy unable to kill Nexium pay-for-delay lawsuit  FiercePharma6 hours ago AstraZeneca PLC, Ranbaxy Laboratories Lose Bid To Derail Nexium Landmark Trial  BioSpace7 hours ago In re: Nexium: Ranbaxy's Motion for a Mistrial to Be Argued Today  JD Supra4 days ago

Ranbaxy Sues FDA for Rejecting Generic Nexium, Valcyte

Indian drugmaker Ranbaxy Laboratories Ltd. (RBXY) sued the U.S. Food and Drug Administration for revoking the company's tentative approval to make generic versions of AstraZeneca Plc (AZN)'s top-selling heartburn pill Nexium and Roche Holding AG ...
 BusinessWeek1 week ago

AstraZeneca Raises Forecast as Nexium Competitor Fails to Appear

Nov. 6 (Bloomberg) -- AstraZeneca Plc, the U.K. drugmaker that fought off a takeover attempt by Pfizer Inc., raised its forecasts for the second time this year after competition for one of its top-selling medicines failed to materialize as expected.
 Washington Post2 weeks ago AstraZeneca Raises Forecast on Lack of Nexium Competitor  Bloomberg2 weeks ago
Business Insider

AstraZeneca Needs to Account for Next Year's Challenges

body: AstraZeneca is enjoying its stay of execution. A delay to the launch of generics for Nexium, Astra's acid-reflux pill, enabled the U.K. pharmaceutical company again to increase full-year guidance. But with U.S. regulators under pressure to ...
 AAPS Pharmceutica1 week ago AstraZeneca lifts sales forecast as Nexium keeps on giving  Reuters2 weeks ago Nexium reprieve lets AstraZeneca spend, spend, spend to prep for 2015 knockdown  FiercePharma2 weeks ago UPDATE 2-AstraZeneca gets sales boost as Nexium drug keeps on giving  London South East2 weeks ago
Reuters UK

AstraZeneca : touts independence as Nexium drug keeps on giving

AstraZeneca , which saw off a $118 billion bid from Pfizer in May, said quarterly results showed its standalone strength, while recent U.S. tax changes removed much of the case for a new takeover attempt. Britain's second biggest drugmaker raised ...
 4 Traders2 weeks ago UPDATE 3-AstraZeneca touts independence as Nexium drug keeps on giving  Reuters2 weeks ago AstraZeneca touts independence as Nexium drug keeps on giving  Yahoo! UK and Ireland2 weeks ago AstraZeneca results show firm's strength  Irish Examiner2 weeks ago

Delayed Generic Nexium Competition Leads to Strong 3Q, but U.S. Pricing Pressures Weigh on Outlook

We don't recognize that email. Please try again. Forgot Password? Password Please enter your password. The password you entered does not match our records. Please try again. Our records show you have a Morningstar account, but you are not ...
 Morningstar.com2 weeks ago

BRIEF-AstraZeneca CEO says not sure how to read Ranbaxy announcement on Nexium

Nov 6 (Reuters) - AstraZeneca CEO and CFO, in call with analysts: * CEO says "not totally sure" how to read Ranbaxy announcement on generic Nexium * CEO says still assuming no generic Nexium in U.S. this year * CFO says U.S. generic Nexium ...
 Reuters2 weeks ago
Business Standard

Ranbaxy's troubled units stand in the way of big profits

ith its plants in India barred from selling in the US, Ranbaxy has been unable to reap the windfall from Nexium, one of the best-selling drugs to go off patent Digbijay Mishra | New Delhi November 5, 2014 Last Updated at 22:35 IST In the world of ...
 Business Standard2 weeks ago
Business Standard

Ranbaxy might lose Nexium exclusivity

Ranbaxy might lose a key six-month exclusivity period for the generic version of Nexium - a blockbuster drug from AstraZeneca - if it fails to get regulatory clearance for the US market by the end of November. The drug maker is awaiting approval for ...
 Business Standard4 weeks ago Ranbaxy may lose exclusivity on Nexium generic  Livemint.com2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less